Proteinuria Treatment Market

Increasing incidences of infectious diseases

The prevalence of kidney disease is on the rise worldwide due to factors such as increasing incidence of diabetes and rising obesity rates. As per the World Kidney Day 2022 Campaign, 1 in 10 people worldwide was diagnosed with CKD, and further, it has been estimated that kidney disease-related mortality is persistently increasing and that by 2040, it will be the 5th leading cause of death globally. Moreover, diabetes is a major risk factor for proteinuria. In people with diabetes, high blood sugar levels can damage the kidneys and cause them to leak protein.

According to the International Diabetes Federation Atlas 2022, there were approximately 476 indigenous people suffering from diabetes across 90 countries worldwide. Furthermore, people who are obese are more likely to have proteinuria than people who are not obese. This is because obesity can lead to high blood pressure, inflammation, and stress on the kidneys, which may damage the kidneys. The World Health Organization has reported that more than 1 billion people were diagnosed with obesity worldwide in 2022.

Therefore, increasing incidences of kidney failure or mild kidney diseases are boosting the growth of the Proteinuria Treatment Market.

The Global Proteinuria Treatment Market Industry is projected to experience substantial growth in the coming years. With a market valuation of 2.2 USD Billion in 2024, it is anticipated to reach 4.7 USD Billion by 2035. This growth trajectory indicates a robust compound annual growth rate (CAGR) of 7.15% from 2025 to 2035. Such projections reflect the increasing recognition of proteinuria as a critical health issue and the corresponding need for effective treatment options. The anticipated expansion of the market underscores the importance of ongoing research and development efforts aimed at improving therapeutic strategies for managing proteinuria.

The global population is aging, which is contributing to the growth of the Global Proteinuria Treatment Market Industry. Older adults are at a higher risk for developing kidney-related issues, including proteinuria, due to the natural decline in kidney function with age. As the geriatric population continues to expand, healthcare providers are increasingly focused on developing and implementing effective treatment strategies for this demographic. This trend is likely to drive demand for proteinuria treatments, as older adults often have multiple comorbidities that complicate their health management. The market's growth trajectory is expected to reflect this demographic shift, with significant implications for healthcare systems worldwide.

The emergence of novel therapeutic options for managing proteinuria is a key driver of the Global Proteinuria Treatment Market Industry. Recent advancements in pharmacotherapy, including the development of angiotensin receptor blockers and other innovative medications, are providing new avenues for treatment. These therapies not only aim to reduce protein levels in urine but also address the underlying causes of kidney damage. As these new treatments gain regulatory approval and become available to patients, the market is likely to experience increased growth. The introduction of effective therapies is expected to enhance patient outcomes and satisfaction, further stimulating demand within the proteinuria treatment sector.

Technological advancements in diagnostic tools are significantly influencing the Global Proteinuria Treatment Market Industry. Enhanced methods for detecting proteinuria, such as urine dipstick tests and more sophisticated laboratory assays, allow for earlier and more accurate diagnosis. This increased diagnostic capability may lead to earlier intervention and treatment, potentially improving patient outcomes. As healthcare providers become more adept at identifying proteinuria, the demand for targeted therapies is likely to rise. This trend aligns with the anticipated growth of the market, which is projected to expand at a CAGR of 7.15% from 2025 to 2035, reflecting the importance of timely diagnosis in managing kidney health.

There is a noticeable increase in awareness and education initiatives regarding kidney health, which is driving the Global Proteinuria Treatment Market Industry. Public health campaigns and educational programs aimed at informing patients about the risks associated with proteinuria and chronic kidney disease are becoming more prevalent. This heightened awareness encourages individuals to seek medical advice and undergo testing, leading to a greater demand for treatment options. As a result, healthcare systems are likely to allocate more resources towards managing proteinuria, further propelling market growth. The emphasis on education is expected to contribute to the market's expansion, aligning with the projected increase in market value over the coming years.

The rising incidence of chronic kidney diseases globally is a primary driver of the Global Proteinuria Treatment Market Industry. As more individuals are diagnosed with conditions such as diabetes and hypertension, which are known to contribute to kidney damage, the demand for effective proteinuria treatments is expected to surge. In 2024, the market is valued at approximately 2.2 USD Billion, reflecting the urgent need for therapeutic interventions. This trend is likely to continue, as projections indicate that by 2035, the market could reach 4.7 USD Billion, highlighting the critical role of addressing proteinuria in managing chronic kidney diseases.

By region, the study segments the market into North America, Europe, Asia-Pacific, and the rest of the world. In North America, the proteinuria treatment market held the largest market share in 2022 due to the presence of major players in the US such as Chinook Therapeutics, Inc. (US), Travere Therapeutics (US), and Pfizer, Inc. (US). In addition, the rising incidences of IgAN are fueling the North America region’s growth.

As per the National Kidney Foundation, in March 2023, approximately 150,000 people in the US were diagnosed with IgAN, which is a rare kidney disease (RKD) that may lead to kidney failure due to glomerular disease.

Hence, the presence of major players in the region and increasing incidences of IgAN, a rare disease, are fostering the growth of the North American proteinuria treatment market.

Further, the major countries studied are: The US, Canada, France, Germany, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

FIGURE 3: PROTEINURIA TREATMENT MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

The European proteinuria treatment market accounted for the second-largest market share due to growing incidences of chronic kidney diseases. The European Union announced in February 2022 that approximately 100 million people will suffer from chronic kidney disease (CKD) in Europe by 2040, which is a lucrative opportunity for the proteinuria treatment market. Proteinuria is found in all CKD patients because CKD patients’ kidneys are unable to filter protein due to damage to the kidney arteries.

Furthermore, the Germany proteinuria treatment market held the largest market in 2022, and the UK proteinuria treatment market is projected to be the fastest-growing market in the Europe region.

The Asia-Pacific proteinuria treatment market is the fastest-growing region from 2023 to 2032, owing to the growing incidence of kidney diseases and the rising geriatric population in the region. In March 2022, the George Institute revealed that major cases of CKD have been found in China and India due to the presence of a larger population and increased cases of diabetes in the eastern, southern, and south-eastern regions of Asia. Moreover, as per Johns Hopkins University (US), there is a 50% chance of having CKD among 75-year-old people.

Additionally, through secondary research, it has been found that the geriatric population is living in Asian countries, mostly in East and Northeast Asia, with approximately 329 million in 2022. Furthermore, the China proteinuria treatment market accounted for the largest market share in 2022, and the India proteinuria treatment market is projected to be the fastest-growing market in the Asia-Pacific region.

Major market players are extensively spending on R&D to extend their service offering, which contributes to the growth of the proteinuria treatment market. Moreover market participants are also growing their worldwide footprint through various strategic initiatives such as the launch of a new product, contractual agreements, mergers and acquisitions, investments, and collaboration with other market participants.

Travere Therapeutics (US) is a biopharmaceutical company focused on identifying, developing, acquiring, and commercializing innovative therapies to improve the lives of patients with rare diseases. It has a presence in North America and Europe. Furthermore, in February 2023, Travere Therapeutics (US) received US Food and Drug Administration approval for FILSPARI. It is the first and only non-immunosuppressive therapy approved for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN).